Can 3M Navigate Legal Risks to Sustain Recent Gains?
July 12, 2025 Netflix Stock Analysis: Is the King Still Reigning?
July 11, 2025 The Harsh Truth: Saving Won’t Make You Rich
July 10, 2025 Moving Out of State from Rockville? Start Here
July 10, 2025 Drive Like Royalty: Best Exotic Cars to Rent in Monaco in 2025
July 10, 2025 2025 Altseason: The Next Frontier in Crypto Growth
Pfizer (PFE) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: July 19, 2025 (17:09)
Sector: HealthcareThe share price of Pfizer Inc. (PFE) now
News Impact Analyzer
Full report
This Week
|
Na | Impact: Na | News: 4 |
Previous Week
|
Bearish | Impact: 1.88 | News: 5 (1/2/2) |
Two Weeks Ago
|
Bullish | Impact: 1.14 | News: 2 (1/0/1) |
Three Weeks Ago
|
Bullish | Impact: 1.13 | News: 3 (1/1/1) |
Analysts predictions
Full report
This Week
|
Neutral | Opinions: 1 |
Previous Week
|
Bullish | Opinions: 3 (2/0/1) |
Two Weeks Ago
|
Neutral | Opinions: Na |
Three Weeks Ago
|
Neutral | Opinions: 3 (1/1/1) |
Analyzing the Most Important PFE news

Dividend Updates: Pfizer and Industry Giants Set Payout Plans


Viatris Faces Setback in Eye Disorder Therapy—Potential Ripple Effect on Pfizer


Pfizer and Bristol-Myers Slash Eliquis Price by 40% in Patient-Centric Move

Historical and forecast chart of Pfizer stock
The chart below shows the historical price of Pfizer stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Pfizer stock price can be found in the table below.
Long-term forecasts by years.
Pfizer Inc. Analysts predictions review

Pfizer's stock trajectory appears moderately positive, driven by pipeline diversification, particularly in high-margin segments like oncology and rare diseases. Strategic acquisitions and R&D investments bolster innovation, creating longer-term growth opportunities despite short-term pressures from declining COVID-related revenues. Institutional interest in options activity signals growing investor confidence, while shareholder-focused measures such as dividends and buybacks support sustained optimism. Macroeconomic headwinds, including pricing pressures and regulatory risks, remain noteworthy but are mitigated by Pfizer's strong financial position and adaptability to market changes.

Pfizer: Bullish Signals Emerge Amid Options Surge

Pfizer's recent surge in options activity suggests growing investor confidence, reflecting speculation on positive developments in its pipeline or financial performance. According to the author, this bullish flow in the derivatives market demonstrates heightened interest from institutional players, often a precursor to favorable stock movements.
The Role of Fundamental Drivers
Beyond options activity, market sentiment may also be buoyed by Pfizer's robust portfolio diversification and advancements in its drug pipeline. Key developments in high-revenue products or successful clinical trials could significantly impact future earnings, reinforcing a favorable outlook for the stock.
Macroeconomic factors, such as regulatory shifts or interest rate changes, warrant attention but appear less critical in influencing Pfizer’s trajectory in the near term. However, with a strong balance sheet and a defensible position in the pharmaceutical market, the company remains well-prepared to navigate external challenges.

Pfizer’s Path to Revitalizing Growth Amid Challenges in the Pharmaceutical Sector

Pfizer's recent diversification efforts, including its focus on developing innovative therapeutics and expanding its vaccine portfolio, are emphasized as pivotal growth drivers. These initiatives are likely to bolster its competitive position in the pharmaceutical market, potentially mitigating some pressures from patent expirations and generic competition. According to the author, this strategic pivot could enhance Pfizer’s revenue prospects in the near term.
Key Factors Driving PFE's Performance
Operational challenges, particularly a decline in COVID-related revenue, remain significant hurdles in Pfizer's short-term financial performance. The author notes that while these declines weigh on near-term growth, the company’s broader pipeline promises long-term opportunities, provided it can execute effectively on new product launches.
Further industry-wide dynamics, such as the impact of regulatory scrutiny and pricing pressures in the U.S. healthcare system, present additional risks to Pfizer's stock price. However, the author concludes that proactive measures, including cost management and partnerships, could offset some of these headwinds, creating a foundation for sustainable profitability.

Pfizer's Strategic Resurgence: A Catalyst for Long-Term Growth

Pfizer's current market position reflects a transitional phase, emphasizing the company’s capacity to rebuild its pipeline and diversify revenue streams. The author highlights the significance of recent portfolio expansions, particularly in oncology and rare diseases, which offer high-margin opportunities. These efforts are expected to mitigate revenue pressures stemming from declining COVID-19-related product sales.
Pipeline Innovation and Strategic Acquisitions
The analysis underscores Pfizer's aggressive focus on next-generation therapeutics through a combination of R&D investments and strategic acquisitions. This pivot into innovative healthcare solutions positions the company favorably in addressing unmet medical needs, providing a strong competitive moat in the industry. Additionally, the commentary elaborates on Pfizer's financial health, with a robust balance sheet supporting both operational initiatives and shareholder returns. The company's ability to sustain shareholder-friendly policies, such as dividends and buybacks, enhances investor confidence in its turnaround potential.
Lastly, the author addresses macroeconomic headwinds, including pricing pressures and regulatory uncertainties. However, these risks are counterbalanced by the company's adaptability and innovation-driven strategies, which are likely to support its stock performance over the medium to long term.
Pfizer's diversification of its product pipeline stands out as a cornerstone of its current strategy. The company's ongoing investment in innovative therapies and vaccines, including advancements in mRNA technology, signals a commitment to long-term growth, bolstering investor confidence during periods of market volatility.
Key Drivers Supporting PFE Outlook
Strong cash flow generation coupled with disciplined capital allocation further reinforces Pfizer's financial stability. The flexibility to fund strategic acquisitions or shareholder returns provides a safety net and a potential catalyst for upward stock price movement.
Concerns over patent expirations and generic competition remain a headwind, but the company's focus on new launches and lifecycle management helps mitigate the risk. These efforts underscore its ability to sustain revenue growth despite market pressures.
Macroeconomic conditions, including healthcare spending trends, play a significant role in Pfizer's near-term outlook. As global demand for innovative treatments continues to rise, the company is well-positioned to capitalize on favorable tailwinds in the sector.
Pfizer's historically strong dividend payouts make its stock attractive to income-focused investors, especially in a low-interest-rate environment. The reliability of these payments suggests stability, but any disruption tied to revenue will likely impact its ability to sustain and grow dividends.
Impact of Patent Expirations and Market Strategy
The looming patent cliff poses significant challenges, threatening a sizable portion of Pfizer's existing revenue streams as generic competition intensifies. The company's response, likely through innovation and acquisitions, will be crucial to offset revenue shrinkage and maintain market confidence.
The author highlights concerns about the broader pharmaceutical landscape, emphasizing how pricing pressures and regulatory scrutiny could pose headwinds for Pfizer's profitability. These external factors will likely magnify volatility in stock performance over the near term.
Pfizer faces significant challenges stemming from declining revenues in its COVID-19 vaccine and antiviral franchise, as demand tapers in the post-pandemic landscape. This contraction in key product revenues represents a critical downside risk for near-term financial performance, as highlighted by the author.
Pipeline delays in high-potential drug launches exacerbate the financial strain, with timelines potentially impacting profitability and investor sentiment. Array underscores these operational issues as pivotal in shaping market perception and stock valuation.
Broader Business Implications
Concerns surrounding the company’s lack of diversification within growth-driving segments further cloud its long-term trajectory. The author's analysis points to increased reliance on acquisitions to maintain growth, which could lead to inefficiencies or heightened debt burdens if poorly executed.
Valuation metrics indicate that despite the stock's current weakness, it may remain unattractive for new investment, given limited short-term catalysts. Investor caution is likely warranted until clearer signals of operational improvements or pipeline success emerge.
Pfizer's focus on R&D optimization continues to enhance its pipeline innovation, driving potential revenue growth through newer high-value drugs. The author underscores that this strategic alignment strengthens Pfizer's competitive standing, especially in markets with surging demand for cutting-edge therapeutics.
Dividend Stability and Market Position
Additionally, its secure dividend policy acts as a stabilizing force, attracting risk-averse investors during volatile market phases. The emphasis on predictable cash flow generation supports long-term shareholder confidence while reinforcing a balanced risk-return profile.
Finally, Pfizer's ability to deliver meaningful clinical advancements while maintaining financial discipline suggests resilience in the face of broader industry challenges. The targeted approach to operating efficiency further improves the company's ability to adapt to dynamic healthcare trends.
The article outlines a significant issue for Pfizer (PFE), as the failure of its oral obesity drug highlights broader weaknesses in its R&D pipeline. This failure has immediate implications for revenue forecasts and investor confidence, as the treatment was anticipated to tap into a burgeoning global demand for obesity solutions, an area increasingly becoming a pharmaceutical growth driver. The missed opportunity underscores the company’s dependence on innovation within high-growth therapeutic areas.
Pipeline Execution and Future Prospects
Beyond the obesity drug setback, the analysis points to systemic challenges in Pfizer's R&D strategy, suggesting inefficiencies in translating promising research into commercially viable products. The narrative positions the company as underperforming relative to peers in addressing industry shifts, including competition in oncology, rare diseases, and immunotherapy. This challenge could exacerbate long-term growth concerns among investors.
The author also touches upon potential implications for Pfizer's financial flexibility amid large-scale investments in acquisitions and research to invigorate its pipeline. While these initiatives aim to offset losses from patent expirations, strained capital allocation could limit the company's ability to maintain dividends and pursue value-accretive opportunities in the near term, affecting its attractiveness to income-focused investors.
Pfizer’s enhanced cost controls are expected to bolster its bottom line by optimizing operational efficiency and reallocating resources to high-potential areas. This approach demonstrates the company’s commitment to margin preservation amidst fluctuating revenues, which could stabilize its stock performance in the near term.
The oncology pipeline, a key growth driver, has attracted investor attention due to promising developments and high unmet medical needs in cancer treatment. According to the author, successful advancements in this segment would showcase Pfizer’s innovation capabilities and potentially lead to long-term revenue sustainability, providing a positive catalyst for its stock.
Assessing the Factors Impacting Pfizer’s Outlook
Regulatory challenges, while not explicitly emphasized, remain critical as they influence the launch timelines and marketability of new drugs. Addressing these hurdles effectively can mitigate risks and enhance investor confidence, impacting near-term share movements.
Lastly, macroeconomic conditions such as interest rates and inflation could also influence Pfizer’s cost structures and consumer demand in the pharmaceutical sector. These external factors, if managed prudently, would deem the stock resilient in volatile markets.
Pfizer's focus on developing PD1/VEGF bispecific therapy highlights its commitment to addressing complex oncology needs and tapping into high-growth markets. The author emphasizes the therapy’s promising clinical data and underscores its potential to strengthen Pfizer's competitive positioning in the highly lucrative cancer treatment space. Near-term stock movement could benefit from positive sentiment tied to clinical milestones and market adoption prospects.
Examining Revenue and Pipeline Diversification
The article discusses Pfizer’s diversification efforts through partnerships like Instil, which bolster its immunotherapy pipeline. By expanding into innovative treatment modalities, Pfizer reduces dependency on legacy products, providing investors with greater visibility into sustained revenue growth. This diversification strategy could enhance long-term valuation, provided these therapies receive favorable regulatory and market outcomes.
The potential for further operational scaling and investment in R&D demonstrates Pfizer's foresight in capturing future demand. The author insightfully points out how strategic reinvestment positions Pfizer to weather competitive pressures and maintain earnings stability, which is key for near-term investor confidence.
Pfizer's current valuation suggests an attractive entry point for investors. The stock trades at a discount relative to historical multiples and sector peers, underpinned by expectations of recovery in key revenue streams.
Pipeline innovation remains a focal strength for Pfizer, with the author highlighting its robust late-stage drug candidates. This could significantly impact long-term growth potential, particularly with notable assets in immunology, oncology, and infectious diseases.
Strategic Catalysts and Revenue Drivers
Post-COVID product demand normalization has raised concerns around revenue headwinds, yet management's guidance underscores confidence in balancing such declines. Vaccine and therapeutic diversification efforts are likely to stabilize earnings and alleviate volatility caused by pandemic-specific contributions.
Shareholder returns through dividends and buybacks further strengthen the case for PFE as a solid value play. The author emphasizes these capital allocative strategies as integral to maintaining investor confidence and ensuring reliable income generation.
Pfizer's partnership with 3SBio underscores the company’s ongoing efforts to penetrate the Chinese biopharmaceutical market, a region with significant growth potential due to its robust demand for innovative biologics. By leveraging 3SBio's local expertise, Pfizer aims to fast-track product approvals and gain a competitive edge, which could fuel top-line growth and positively influence investor sentiment.
Strategic Impact of the 3SBio Partnership
The deal further aligns with Pfizer’s strategy to diversify its revenue streams as patent cliffs threaten its existing blockbuster products. Collaborations like these play a vital role in counteracting revenue declines and are likely to support stock resilience in the near term.
Additionally, the move reflects Pfizer’s priorities to reinforce its R&D pipeline in areas of high unmet medical need. Improved portfolio visibility through such initiatives could enhance the company’s medium- to long-term valuation, attracting both growth-focused and value-oriented investors.
Comprehensive Analysis of Pfizer (PFE) Stock Market Performance
Our multifaceted analysis of Pfizer's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Pfizer stock?
- When should I record a loss on Pfizer stock?
- What are analysts' forecasts for Pfizer stock?
- What is the future of Pfizer stock?
We forecast Pfizer stock performance using neural networks based on historical data on Pfizer stocks.
The Bright Future of PFE Stocks: An Unfolding Opportunity
In the world of high-stakes investing, few opportunities are as compelling as the case of Pfizer Inc. (NYSE:PFE). This pharmaceutical giant, standing on the threshold of its 176th year, has experienced a roller coaster in the stock market, touching a decade-low low of $26.93 per share. To understand the PFE stock forecast, it is crucial to investigate the events and factors poised to influence its performance.
The capability to predict PFE stock rates with high accuracy hinges significantly on analyzing the company’s strong fundamentals and upcoming market dynamics. Recently, the valuation of Pfizer has reached a depressed level, essentially providing a lucrative buying opportunity. Despite facing a decline in COVID-19 related product sales, Pfizer reported a commendable 7% operating sales growth in 2023, propelled by new product launches and the consistent growth of existing ones.
Factors Influencing PFE Stock Performance
Looking ahead, several core elements will play pivotal roles in shaping Pfizer’s stock trajectory. Firstly, the heavy influx of COVID-19 related revenue has bolstered Pfizer’s financial position, rendering the acquisition of Seagen—a leader in antibody-drug conjugate technology—a strategic masterstroke. This move positions Pfizer ahead in a competitive race within the pharma industry.
Moreover, while some of Pfizer’s key drugs are on the verge of hitting a patent cliff, the company’s robust and diverse pipeline promises not just to offset, but potentially eclipse, any potential shortfalls. Given these dynamics, forecasting a substantial upside for PFE stock seems not just optimistic but grounded in tangible facts and figures.
In conclusion, when contemplating the PFE stock buy or sell dilemma, it’s imperative to consider the projected EPS growth, the anticipated rise in EBITDA margins, and the transformative potential of Pfizer’s product pipeline. With an attractive dividend yield forecast of 6.19% for FY2024, the question isn’t so much ‘will PFE stock go up?’ but rather, ‘how high?’ As such, the PFE stock price target points towards an optimistic upward trend, making PFE stock an attractive proposition for both investors and analysts alike.
Pfizer Inc. stands tall as one of the global giants in the pharmaceutical industry, hailing from the United States. This powerhouse is behind a suite of well-known medications that have become household names. They’ve got Lipitor to keep cholesterol in check, Lyrica for nerve and muscle pain relief, Diflucan as an antifungal go-to, and Zithromax for bacterial infections.
There’s also the famed blue pill, Viagra, giving hope to those grappling with erectile dysfunction, while Celebrex battles arthritis and other forms of pain. Sermion comes to the aid of those with cognitive issues, Dostinex addresses hormonal imbalances, and Champix lends a hand to those determined to quit smoking.
Pfizer Inc. News influencing stock rates

As of now, Panda has combed through 14 news items directly related to PFE from the last 30 days. Out of these, 3 clearly showcase a bullish trend, while 4 display bearish tendencies, and 7 events are neutral.
The strength of the bearish trend is dominating bullish sentiments by 1.22 times, indicating that the current news landscape is negatively impacting the company's stock prices in the foreseeable future.
The news analyzed fell within the period from Jun 25, 2025, to Jul 18, 2025.
ViiV Scales Generic HIV Treatment Access, Impacts GSK and Partners


FDA's Transparency Move: Revealing Rejected Drugs to Accelerate Approvals


Pfizer's Xtandi Surpasses Secondary Goal in Prostate Cancer Trial


Trump Eyes Unprecedented 200% Tariffs on Pharmaceuticals


Pfizer's Corporate Shakeup: Longtime Affairs Chief Steps Down


UK Warns of Rare Guillain-Barré Risk Tied to Pfizer's RSV Vaccine


CDC Greenlights RSV Vaccine for High-Risk Adults 50-59


Pfizer Halts Phase 2 Trial for Key Cancer Drug: Recruitment Challenges Cited


Pfizer's Breakthrough Therapy for Hemophilia Hits Phase 3 Milestone


Pfizer Maintains $0.43 Dividend Amid 7%+ Forward Yield


Pfizer daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jul 21 | 24.63 | 24.39 | 24.90 | 2.09 |
Jul 22 | 24.88 | 24.63 | 25.20 | 2.30 |
Jul 23 | 24.81 | 24.43 | 25.05 | 2.53 |
Jul 24 | 24.32 | 23.97 | 24.69 | 3.01 |
Jul 25 | 23.96 | 23.81 | 24.14 | 1.39 |
Jul 26 | 24.10 | 23.77 | 24.46 | 2.89 |
Jul 27 | 24.27 | 23.97 | 24.53 | 2.34 |
Jul 28 | 24.61 | 24.06 | 24.99 | 3.87 |
Jul 29 | 24.51 | 24.18 | 25.02 | 3.50 |
Jul 30 | 24.53 | 24.15 | 25.01 | 3.57 |
Jul 31 | 24.41 | 23.94 | 24.95 | 4.22 |
Aug 01 | 24.66 | 24.34 | 25.00 | 2.67 |
Aug 02 | 25.09 | 24.64 | 25.36 | 2.93 |
Aug 03 | 25.23 | 24.96 | 25.38 | 1.67 |
Aug 04 | 25.76 | 25.49 | 26.38 | 3.46 |
Aug 05 | 26.02 | 25.47 | 26.19 | 2.85 |
Aug 06 | 25.82 | 25.66 | 26.27 | 2.35 |
Aug 07 | 26.37 | 26.22 | 26.66 | 1.69 |
Aug 08 | 26.38 | 26.03 | 26.79 | 2.92 |
Aug 09 | 25.93 | 25.67 | 26.16 | 1.91 |
Aug 10 | 26.28 | 25.82 | 26.87 | 4.06 |
Aug 11 | 25.74 | 25.24 | 25.95 | 2.81 |
Aug 12 | 26.49 | 26.07 | 26.74 | 2.56 |
Aug 13 | 26.72 | 26.55 | 27.34 | 2.99 |
Aug 14 | 26.63 | 26.37 | 27.02 | 2.45 |
Aug 15 | 27.40 | 27.07 | 27.72 | 2.40 |
Aug 16 | 26.81 | 26.17 | 27.09 | 3.50 |
Aug 17 | 26.47 | 25.86 | 27.09 | 4.73 |
Aug 18 | 25.85 | 25.60 | 26.05 | 1.76 |
Aug 19 | 25.92 | 25.52 | 26.16 | 2.50 |
Pfizer Daily Price Targets
Pfizer Stock Forecast 07-21-2025.
Forecast target price for 07-21-2025: $24.63.
Positive dynamics for Pfizer shares will prevail with possible volatility of 2.048%.
Pessimistic target level: 24.39
Optimistic target level: 24.90
Pfizer Stock Forecast 07-22-2025.
Forecast target price for 07-22-2025: $24.88.
Positive dynamics for Pfizer shares will prevail with possible volatility of 2.251%.
Pessimistic target level: 24.63
Optimistic target level: 25.20
Pfizer Stock Forecast 07-23-2025.
Forecast target price for 07-23-2025: $24.81.
Negative dynamics for Pfizer shares will prevail with possible volatility of 2.467%.
Pessimistic target level: 24.43
Optimistic target level: 25.05
Pfizer Stock Forecast 07-24-2025.
Forecast target price for 07-24-2025: $24.32.
Negative dynamics for Pfizer shares will prevail with possible volatility of 2.925%.
Pessimistic target level: 23.97
Optimistic target level: 24.69
Pfizer Stock Forecast 07-25-2025.
Forecast target price for 07-25-2025: $23.96.
Negative dynamics for Pfizer shares will prevail with possible volatility of 1.370%.
Pessimistic target level: 23.81
Optimistic target level: 24.14
Pfizer Stock Forecast 07-26-2025.
Forecast target price for 07-26-2025: $24.10.
Positive dynamics for Pfizer shares will prevail with possible volatility of 2.808%.
Pessimistic target level: 23.77
Optimistic target level: 24.46
PFE (PFE) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jul. | 24.90 | 24.02 | 26.62 | 9.76 |
Aug. | 24.87 | 23.22 | 26.60 | 12.71 |
Sep. | 25.37 | 24.57 | 26.10 | 5.86 |
Oct. | 25.91 | 25.38 | 26.52 | 4.31 |
Nov. | 24.09 | 23.47 | 25.55 | 8.15 |
Dec. | 24.83 | 23.38 | 26.20 | 10.75 |
Pfizer forecast for this year
Pfizer Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $24.8958. Pessimistic: $24.02. Optimistic: $26.62
Pfizer Stock Prediction for Aug 2025
An downtrend is forecast for this month with an optimal target price of $24.8733. Pessimistic: $23.22. Optimistic: $26.60
Pfizer Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $25.3658. Pessimistic: $24.57. Optimistic: $26.10
Pfizer Stock Prediction for Oct 2025
An uptrend is forecast for this month with an optimal target price of $25.9137. Pessimistic: $25.38. Optimistic: $26.52
Pfizer Stock Prediction for Nov 2025
An downtrend is forecast for this month with an optimal target price of $24.0946. Pessimistic: $23.47. Optimistic: $25.55
Pfizer Stock Prediction for Dec 2025
An uptrend is forecast for this month with an optimal target price of $24.8319. Pessimistic: $23.38. Optimistic: $26.20
Pfizer (PFE) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 25.59 | 23.84 | 26.61 | 10.39 |
Feb | 24.44 | 23.36 | 26.00 | 10.15 |
Mar | 23.34 | 22.02 | 23.80 | 7.50 |
Apr | 25.19 | 23.40 | 26.25 | 10.88 |
May | 23.83 | 22.76 | 25.20 | 9.70 |
Jun | 24.15 | 22.46 | 25.15 | 10.72 |
Jul | 24.61 | 23.96 | 25.89 | 7.44 |
Aug | 26.05 | 25.55 | 26.61 | 3.96 |
Sep | 27.03 | 26.01 | 28.54 | 8.87 |
Oct | 26.45 | 25.78 | 28.30 | 8.91 |
Nov | 27.85 | 25.97 | 28.90 | 10.15 |
Dec | 26.72 | 25.16 | 28.19 | 10.75 |
Pfizer (PFE) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 25.67 | 23.93 | 27.21 | 12.05 |
Feb | 23.56 | 22.33 | 24.98 | 10.61 |
Mar | 23.63 | 22.69 | 25.12 | 9.65 |
Apr | 23.63 | 22.22 | 24.71 | 10.07 |
May | 22.44 | 21.00 | 23.99 | 12.46 |
Jun | 22.11 | 20.92 | 23.21 | 9.86 |
Jul | 22.37 | 20.82 | 23.54 | 11.55 |
Aug | 23.40 | 22.81 | 25.08 | 9.07 |
Sep | 22.37 | 21.18 | 23.27 | 9.00 |
Oct | 21.86 | 20.72 | 23.38 | 11.36 |
Nov | 21.25 | 19.72 | 22.61 | 12.77 |
Dec | 19.44 | 18.16 | 20.10 | 9.66 |
Pfizer information and performance
235 E 42ND ST, NEW YORK, NY, US
Market capitalization of the Pfizer Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of PFE shares in the company outstanding by the market price of one share.
EBITDA of Pfizer is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Pfizer (PFE) stock dividend
Pfizer last paid dividends on 05/09/2025. The next scheduled payment will be on 06/13/2025. The amount of dividends is $1.69 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Pfizer Stock)
Should I Buy Pfizer Shares in 2025 year?
Does Pfizer pay dividends?
Which economic sector do Pfizer's shares belong to?
Which other securities belong to the same sector as Pfizer's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.